keyword
MENU ▼
Read by QxMD icon Read
search

Melanoma intralesional

keyword
https://www.readbyqxmd.com/read/27922859/fdg-pet-ct-for-monitoring-response-of-melanoma-to-the-novel-oncolytic-viral-therapy-talimogene-laherparepvec
#1
Matthew F Covington, Clara N Curiel, Lois Lattimore, Ryan J Avery, Phillip H Kuo
61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months...
December 3, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27895500/efficacy-and-safety-of-talimogene-laherparepvec-versus-granulocyte-macrophage-colony-stimulating-factor-in-patients-with-stage-iiib-c-and-ivm1a-melanoma-subanalysis-of-the-phase-iii-optim-trial
#2
Kevin J Harrington, Robert Hi Andtbacka, Frances Collichio, Gerald Downey, Lisa Chen, Zsolt Szabo, Howard L Kaufman
OBJECTIVES: Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in 436 patients with unresectable stage IIIB-IVM1c melanoma. The median overall survival (OS) was longer versus GM-CSF in patients with earlier-stage melanoma (IIIB-IVM1a)...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27785448/spotlight-on-talimogene-laherparepvec-for-the-treatment-of-melanoma-lesions-in-the-skin-and-lymph-nodes
#3
REVIEW
Marlana Orloff
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list of effective therapies for melanoma. Though the Phase III OPTiM trial has demonstrated its efficacy as a single agent, the target patient population remains narrow. With numerous effective and tolerable treatments available for unresectable and metastatic melanoma, intralesional therapies such as T-VEC are still finding their niche...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27725148/conjunctival-tumors-in-5002-cases-comparative-analysis-of-benign-versus-malignant-counterparts-the-2016-james-d-allen-lecture
#4
Carol L Shields, Adel E Alset, Nina S Boal, Mairghread G Casey, Austen N Knapp, Jordan A Sugarman, Marisa A Schoen, Phillip S Gordon, Alexzandra M Douglass, Kareem Sioufi, Emil A T Say, Jerry A Shields
PURPOSE: To evaluate frequency of conjunctival tumors in all ages and compare benign vs malignant counterparts. DESIGN: Retrospective series. METHODS: setting: Tertiary referral center. STUDY POPULATION: Total of 5002 patients. OBSERVATION: Clinical features. MAIN OUTCOME MEASURE: Differentiation of benign from malignant counterparts. RESULTS: The tumor was benign (52%), premalignant (18%), or malignant (30%)...
January 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27606149/melanocytic-nevus-of-the-tarsal-conjunctiva
#5
Bülent Yazıcı, Ayşe Dolar Bilge, Ayşe Yağcı, Faisal Naqadan, Filiz Altıntepe
BACKGROUND: Melanocytic nevus is a rare occurrence in the tarsal conjunctiva and only 7 well-described cases have been reported previously in the English literature. CASE REPORT: The medical records of 4 patients with tarsal conjunctival melanocytic nevus were reviewed, together with the relevant literature. All patients (3 women and 1 man; age range: 17 - 40 years) had been referred with a suspicion of melanoma. There was one tarsal nevus in the lower eyelid in 3 patients and 2 nevi in the upper eyelid in 1 patient...
July 2016: Balkan Medical Journal
https://www.readbyqxmd.com/read/27602429/intralesional-and-systemic-immunotherapy-for-metastatic-melanoma
#6
Carrie Luu, Nikhil I Khushalani, Jonathan S Zager
INTRODUCTION: Immunotherapy has revolutionized the treatment of metastatic melanoma and dramatically improved patient outcomes. Ipilimumab, an inhibitor of cytotoxic T-lymphocyte antigen-4 (CTLA-4), was the first immunotherapeutic agent to demonstrate improved survival in advanced melanoma. More recently, other immune checkpoint inhibitors, including the programmed death-1 (PD-1) inhibitors pembrolizumab and nivolumab, have demonstrated efficacy in locally advanced unresectable and metastatic melanoma...
September 20, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27516203/talimogene-laherparepvec-a-review-in-unresectable-metastatic-melanoma
#7
Karly P Garnock-Jones
Talimogene laherparepvec (Imlygic™) is a first-in-class oncolytic viral immunotherapy derived from herpes simplex virus type 1, which has been genetically modified to increase tumour selectivity and stimulate antitumour immune response. This article reviews the pharmacological properties of intralesional talimogene laherparepvec and its clinical efficacy and tolerability in patients with unresectable metastatic melanoma. In the phase III OPTiM trial, talimogene laherparepvec was more effective than subcutaneous human granulocyte-macrophage colony-stimulating factor (GM-CSF), both in patients with stage IIIB-IV melanoma [intention-to-treat (ITT) population] and in those with stage IIIB-IVM1a disease (in an exploratory subgroup analysis)...
October 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27486853/oncolytic-virus-therapy-a-new-era-of-cancer-treatment-at-dawn
#8
REVIEW
Hiroshi Fukuhara, Yasushi Ino, Tomoki Todo
Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success in immunotherapy using immune checkpoint inhibitors. Oncolytic viruses are defined as genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming the normal tissues. T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe...
October 2016: Cancer Science
https://www.readbyqxmd.com/read/27407058/cutaneous-head-and-neck-melanoma-in-optim-a-randomized-phase-3-trial-of-talimogene-laherparepvec-versus-granulocyte-macrophage-colony-stimulating-factor-for-the-treatment-of-unresected-stage-iiib-iiic-iv-melanoma
#9
Robert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, Sigrun Hallmeyer, Mohammed Milhem, Thomas Amatruda, John J Nemunaitis, Kevin J Harrington, Lisa Chen, Mark Shilkrut, Merrick Ross, Howard L Kaufman
BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). METHODS: Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM-CSF (n = 26)...
December 2016: Head & Neck
https://www.readbyqxmd.com/read/27237868/intralesional-pv-10-for-in-transit-melanoma-a-single-center-experience
#10
Jocelyn Lippey, Rhiannon Bousounis, Cori Behrenbruch, Bartholomew McKay, John Spillane, Michael A Henderson, David Speakman, David E Gyorki
BACKGROUND AND OBJECTIVES: Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities...
September 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27188675/a-review-of-novel-intralesional-therapies-for-melanoma-with-an-emphasis-on-a-potential-combination-approach
#11
COMMENT
Lawrence Chen, Adil Daud
No abstract text is available yet for this article.
May 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27188674/the-role-of-intralesional-therapies-in-melanoma
#12
REVIEW
Sanjiv S Agarwala
The US Food and Drug Administration has been rapidly approving new checkpoint inhibitors and targeted therapies for melanoma and other tumors. Recently, it approved the first intralesional therapy, talimogene laherparepvec (T-VEC), for the treatment of metastatic melanoma lesions in the skin and lymph nodes. Several other intralesional therapies (PV-10, interleukin-12 electroporation, coxsackievirus A21 [CVA21]) are entering later-stage testing. Locally injected agents have clearly shown their ability to produce local responses that can be durable...
May 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27177220/intralesional-rose-bengal-in-melanoma-elicits-tumor-immunity-via-activation-of-dendritic-cells-by-the-release-of-high-mobility-group-box-1
#13
Hao Liu, Pasquale Patrick Innamarato, Krithika Kodumudi, Amy Weber, Satoshi Nemoto, John L Robinson, Georgina Crago, Timothy McCardle, Erica Royster, Amod A Sarnaik, Shari Pilon-Thomas
Intralesional (IL) therapy is under investigation to treat dermal and subcutaneous metastatic cancer. Rose bengal (RB) is a staining agent that was originally used by ophthalmologists and in liver function studies. IL injection of RB has been shown to induce regression of injected and uninjected tumors in murine models and clinical trials. In this study, we have shown a mechanism of tumor-specific immune response induced by IL RB. In melanoma-bearing mice, IL RB induced regression of injected tumor and inhibited the growth of bystander lesions mediated by CD8+ T cells...
June 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27096540/intralesional-incision-biopsy-for-melanoma-diagnosis-the-rules-and-the-exception-to-the-rules
#14
Elvira Moscarella, Giuseppe Argenziano, Claudia Moreno, Simonetta Piana, Aimilios Lallas, Mara Lombardi, Caterina Longo, Gerardo Ferrara
Intralesional (incision) biopsy for melanoma diagnosis can be warranted for large lesions or for lesions whose in toto excision leads to cosmetic and/or functional impairment. However, this diagnostic approach carries a risk of underdiagnosis, if a clinicopathologic diagnostic approach is not implemented. As a rule, in large pigmented lesions from special body areas (scalp and acral skin), clinicodermoscopic differential diagnosis of melanoma includes non-melanocytic skin lesions, or traumatic skin changes, rather then nevi...
April 20, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27059193/melanoma-version-2-2016-nccn-clinical-practice-guidelines-in-oncology
#15
Daniel G Coit, John A Thompson, Alain Algazi, Robert Andtbacka, Christopher K Bichakjian, William E Carson, Gregory A Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C Fields, Martin D Fleming, Rene Gonzalez, Valerie Guild, Allan C Halpern, F Stephen Hodi, Richard W Joseph, Julie R Lange, Mary C Martini, Miguel A Materin, Anthony J Olszanski, Merrick I Ross, April K Salama, Joseph Skitzki, Jeff Sosman, Susan M Swetter, Kenneth K Tanabe, Javier F Torres-Roca, Vijay Trisal, Marshall M Urist, Nicole McMillian, Anita Engh
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections...
April 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27051847/treatment-of-melanoma-in-transit-metastases-with-combination-intralesional-interleukin-2-topical-imiquimod-and-tretinoin-0-1-cream
#16
Jonathan S Leventhal, Ian D Odell, Suguru Imaeda, Emanual Maverakis, Brett A King
No abstract text is available yet for this article.
March 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27020389/satellite-in-transit-metastases-in-rapidly-fatal-conjunctival-melanoma-implications-for-angiotropism-and-extravascular-migratory-metastasis-description-of-a-murine-model-for-conjunctival-melanoma
#17
Raymond L Barnhill, Stéphanie Lemaitre, Christine Lévy-Gabrielle, Manuel Rodrigues, Laurence Desjardins, Rémi Dendale, Anne Vincent-Salomon, Sergio Roman-Roman, Claire Lugassy, Nathalie Cassoux
Little information is currently available concerning loco-regional metastases such as satellite and in transit metastases and their natural history in conjunctival melanoma as compared to cutaneous melanoma. Angiotropism, a marker of extravascular migration of melanoma cells along vascular channels, often appears responsible for microscopic satellite, satellite and in transit metastases development in cutaneous melanoma. In addition, diffuse tissue microscopic satellites are correlated with widespread melanoma dissemination and death...
February 2016: Pathology
https://www.readbyqxmd.com/read/27009452/developments-in-intralesional-therapy-for-metastatic-melanoma
#18
REVIEW
Sarah Sloot, Omar M Rashid, Arnod A Sarnaik, Jonathan S Zager
BACKGROUND: Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing. METHODS: The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review...
January 2016: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/26906132/administration-and-handling-of-talimogene-laherparepvec-an-intralesional-oncolytic-immunotherapy-for-melanoma
#19
Brianna Hoffner, Gail M Iodice, Eduard Gasal
PURPOSE/OBJECTIVES: To describe the administration and handling requirements of oncolytic viruses in the context of talimogene laherparepvec (Imlygic™), a first-in-class oncolytic immunotherapy.
. DATA SOURCES: Study procedures employed in clinical trials, in particular the OPTiM study.
. DATA SYNTHESIS: Evaluation of nursing considerations for administration of talimogene laherparepvec.
. CONCLUSIONS: Talimogene laherparepvec is administered through a series of intralesional injections into cutaneous, subcutaneous, or nodal tumors (with ultrasound guidance as needed) during an outpatient clinic visit...
March 2016: Oncology Nursing Forum
https://www.readbyqxmd.com/read/26898656/intralesional-immunotherapy-as-a-strategy-to-treat-melanoma
#20
Noura Nouri, Claus Garbe
INTRODUCTION: Intralesional immunotherapy supplements systemic treatments and often achieves higher remission rates as compared to systemic therapy. Its indication is metastatic melanoma with limited tumor burden, particularly in loco-regional metastasis and distant soft tissue metastasis. AREAS COVERED: This review describes intralesional immunotherapy with talimogene laherparepvec (T-VEC), with velimogene aliplasmid (Allovectin-7) and with intralesional interleukin-2...
2016: Expert Opinion on Biological Therapy
keyword
keyword
106246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"